[1] Buffolo F, Monticone S, Burrello J, et al.  Is Primary Aldosteronism Still Largely Unrecognized?[J]. Horm Metab Res, 2017, 49(12): 908-914.   doi: 10.1055/s-0043-119755
[2] Monticone S, D'Ascenzo F, Moretti C, et al.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 41-50.   doi: 10.1016/s2213-8587(17)30319-4
[3] Funder JW, Carey RM, Mantero F, et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101(5): 1889-1916.   doi: 10.1210/jc.2015-4061
[4] Wu VC, Chueh SC, Chang HW, et al.  Association of Kidney Function With Residual Hypertension After Treatment of Aldosterone-Producing Adenoma[J]. Am J Kidney Dis, 2009, 54(4): 665-673.   doi: 10.1053/j.ajkd.2009.06.014
[5] Fassnacht M, Arlt W, Bancos I, et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2016, 175(2): G1-G34.   doi: 10.1530/eje-16-0467
[6] Lenders JWM, Eisenhofer G, Reincke M.  Subtyping of Patients with Primary Aldosteronism: An Update[J]. Horm Metab Res, 2017, 49(12): 922-928.   doi: 10.1055/s-0043-122602
[7] Vonend O, Ockenfels N, Gao X, et al.  Adrenal Venous Sampling: Evaluation of the German Conn's Registry[J]. Hypertension, 2011, 57(5): 990-995.   doi: 10.1161/hypertensionaha.110.168484
[8] Sarkar SD, Beierwaltes H, Ice RD, et al.  A new and superior adrenal scanning agent, NP-59[J]. J Nucl Med, 1975, 16(11): 1038-1042.
[9]

Mendichovszky IA, Powlson AS, Manavaki R, et al. Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT[J/OL]. Diagnostics, 2016, 6(4): E42[2019-01-21]. https://www.ncbi.nlm.nih.gov/pubmed/27869719. DOI: 10.3390/diagnostics6040042.
[10] Burton TJ, Mackenzie IS, Balan K, et al.  Evaluation of the Sensitivity and Specificity of 11C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas[J]. J Clin Endocrinol Metab, 2012, 97(1): 100-109.   doi: 10.1210/jc.2011-1537
[11] Heinze B, Fuss CT, Mulatero P, et al.  Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma[J]. Hypertension, 2018, 71(2): 317-325.   doi: 10.1161/hypertensionaha.117.09975
[12] Di Martino M, Sanz IG, de Nova JLM, et al.  NP-59 test for preoperative localization of primary hyperaldosteronism[J]. Langenbecks Arch Surg, 2017, 402(2): 303-308.   doi: 10.1007/s00423-017-1561-1
[13] Hennings J, Lindhe Ö, Bergström M, et al.  [11C] Metomidate Positron Emission Tomography of Adrenocortical Tumors in Correlation with Histopathological Findings[J]. J Clin Endocrinol Metab, 2006, 91(4): 1410-1414.   doi: 10.1210/jc.2005-2273
[14] Hennings J, Sundin A, Hägg A, et al.  11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism[J]. Langenbecks Arch Surg, 2010, 395(7): 963-967.   doi: 10.1007/s00423-010-0681-7
[15] Hahner S, Kreissl MC, Fassnacht M, et al.  Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT[J]. J Clin Endocrinol Metab, 2013, 98(4): 1508-1518.   doi: 10.1210/jc.2012-3045
[16] Philipp-Abbrederis K, Herrmann K, Knop S, et al.  In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma[J]. EMBO Mol Med, 2015, 7(4): 477-487.   doi: 10.15252/emmm.201404698
[17] Abe T, Naruse M, Young Jr WF, et al.  A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism[J]. J Clin Endocrinol Metab, 2016, 101(3): 1008-1015.   doi: 10.1210/jc.2015-3431
[18] Volpe C, Enberg U, Sjögren A, et al.  The Role of Adrenal Scintigraphy in the Preoperative Management of Primary Aldosteronism[J]. Scand J Surg, 2008, 97(3): 248-253.   doi: 10.1177/145749690809700308
[19] Wu MH, Liu FH, Lin KJ, et al.  Diagnostic value of adrenal iodine-131 6-beta-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center in North Taiwan[J]. Nucl Med Commun, 2019, 40(6): 568-575.   doi: 10.1097/mnm.0000000000000987
[20] Lu CC, Wu VC, Wu KD, et al.  Prognostic value of semiquantification NP-59 SPECT/CT in primary aldosteronism patients after adrenalectomy[J]. Eur J Nucl Med Mol Imaging, 2014, 41(7): 1375-1384.   doi: 10.1007/s00259-014-2692-z
[21] Yen RF, Wu VC, Liu KL, et al.  131I-6β-Iodomethyl-19-Norcholesterol SPECT/CT for Primary Aldosteronism Patients with Inconclusive Adrenal Venous Sampling and CT Results[J]. J Nucl Med, 2009, 50(10): 1631-1637.   doi: 10.2967/jnumed.109.064873
[22] Hennings J, Hellman P, Ahlström H, et al.  Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas[J]. Eur J Radiol, 2009, 69(2): 314-323.   doi: 10.1016/j.ejrad.2007.10.024
[23] Zettinig G, Mitterhauser M, Wadsak W, et al.  Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate[J]. Eur J Nucl Med Mol Imaging, 2004, 31(9): 1224-1230.   doi: 10.1007/s00259-004-1575-0
[24] Takanami K, Kaneta T, Morimoto R, et al.  Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?[J]. Ann Nucl Med, 2014, 28(2): 145-153.   doi: 10.1007/s12149-013-0793-6
[25] Patel D, Gara SK, Ellis RJ, et al.  FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization[J]. World J Surg, 2016, 40(3): 683-689.   doi: 10.1007/s00268-015-3242-y